Qualitative Determination of Known Thromboxane Receptors in Human Plasma by LC-MS (Quadrupole Time of Flight)

Abstract

Thromboxane is a potent platelet aggregating agent which also contracts both vascular and non-vascular smooth muscle. Selective agents have been identified which inhibit these actions of thromboxane in a manner consistent with competitive receptor antagonism. Some of these antagonists have potential utility in the treatment of thromboxane-dependent pathologies, particularly within the cardiovascular/renal systems. Classically, receptor types are defined by use of selective antagonists and possible receptor differences derived from differential potency of these antagonists when measured in different tissues. Dazmegrel [3-(1H-imidazole-1-yl-methyl)2-methyl-1H-indole-1-propanoic acid] is persistence as enzyme inhibitors; platelet aggregation inhibitors and Vasodilator Agents. GR32191 (vapiprost) 7-(5-(((1,1'-biphenyl)-4-yl)methoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl)-4-heptanoic acid is a potent and selective thromboxane receptor antagonist. The thromboxane A2/PG endoperoxide receptor inhibitor. Its mechanism is Fibrinolytic Agents; platelet aggregation inhibitors and prostaglandin antagonists. SQ 29548 7-(3-((2((phenylamino)carbonyl)hydrazine)methyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid is a Thromboxane/antagonists & inhibitors. U-46619 (Z)-7-((1R,4S,5S,6R)-6-((E)-3hydroxyoct-1-enyl)-2-oxabicyclo[2.2.1]heptan-5-yl)hept-5Qualitative Determination of Known Thromboxane Receptors in Human Plasma by LC-MS (Quadrupole Time of Flight)